- Home
- CPRX vs IDYA Comparison
CPRX vs IDYA Comparison
Compare CPRX & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- IDYA
- Stock Information
- Founded
- CPRX 2002
- IDYA 2015
- Country
- CPRX United States
- IDYA United States
- Employees
- CPRX N/A
- IDYA N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- IDYA Health Care
- Exchange
- CPRX Nasdaq
- IDYA Nasdaq
- Market Cap
- CPRX 2.6B
- IDYA 2.3B
- IPO Year
- CPRX 2006
- IDYA 2019
- Fundamental
- Price
- CPRX $20.82
- IDYA $26.96
- Analyst Decision
- CPRX Strong Buy
- IDYA Buy
- Analyst Count
- CPRX 5
- IDYA 15
- Target Price
- CPRX $33.20
- IDYA $47.92
- AVG Volume (30 Days)
- CPRX 1.6M
- IDYA 1.2M
- Earning Date
- CPRX 11-05-2025
- IDYA 11-03-2025
- Dividend Yield
- CPRX N/A
- IDYA N/A
- EPS Growth
- CPRX 183.96
- IDYA N/A
- EPS
- CPRX 1.65
- IDYA N/A
- Revenue
- CPRX $558,499,000.00
- IDYA $7,000,000.00
- Revenue This Year
- CPRX $16.51
- IDYA $63.41
- Revenue Next Year
- CPRX $9.58
- IDYA $305.49
- P/E Ratio
- CPRX $12.64
- IDYA N/A
- Revenue Growth
- CPRX 28.55
- IDYA N/A
- 52 Week Low
- CPRX $19.05
- IDYA $13.45
- 52 Week High
- CPRX $26.58
- IDYA $32.67
- Technical
- Relative Strength Index (RSI)
- CPRX 58.08
- IDYA 58.57
- Support Level
- CPRX $19.05
- IDYA $26.88
- Resistance Level
- CPRX $21.07
- IDYA $28.41
- Average True Range (ATR)
- CPRX 0.59
- IDYA 1.01
- MACD
- CPRX 0.16
- IDYA 0.08
- Stochastic Oscillator
- CPRX 60.27
- IDYA 58.38
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.